- Ouro Medicines has launched with $120 million in Series A funding to develop immune reset therapeutics for chronic immune-mediated diseases.
- The funding round was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from GSK, Monograph Capital, and others.

Ouro Medicines has officially launched with $120 million in funding to develop immune reset therapeutics for chronic immune-mediated diseases. The Series A funding round was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with additional support from Monograph Capital, GSK, and other investors.
The company’s main focus is on B cell-mediated diseases, for which existing treatments are often ineffective or associated with high toxicity due to prolonged immunosuppressive therapy. Ouro Medicines is exploring T cell engager antibodies (TCEs), which target and deplete specific pathogenic cells, potentially resetting the immune system to a pre-disease state. This approach could offer long-term remission without the need for continuous immunosuppressive treatments.
Jaideep Dudani, CEO of Ouro Medicines, commented, “We see a tremendous opportunity to define the future of treatment for people with immune-mediated diseases because the standard of care today leaves a lot to be desired. Being able to precisely target cell populations with a high-potency therapeutic is crucial to depleting whole lineages of pathogenic cell populations so that we can achieve immune reset.”
The company’s lead candidate, OM336, is a bispecific TCE targeting BCMA, which is expressed in several B cell subtypes. Ouro Medicines has exclusive rights to the compound outside of Greater China and plans to start Phase 1 trials in 2025. The company aims to address unmet needs in diseases such as systemic lupus erythematosus and rheumatoid arthritis.
Looking forward, Ouro Medicines intends to expand its pipeline with new discovery programs targeting other aspects of B cell biology, leveraging its protein engineering expertise to develop next-generation TCE therapies.